Vaxcyte (PCVX) has dosed the first participant in its Phase 1 trial of VAX-A1, a Group A Strep vaccine candidate. This is a key early step in testing a product aimed at a large unmet medical need.

Despite the positive development for VAX-A1, recent share price momentum has been soft, with the stock down 10.66% on a 30 day share price return and 20.16% on a 90 day share price return, while the 1 year total shareholder return of 28.03% and 5 year total shareholder return of 115.17% indicate a much stronger long term picture.

If Vaxcyte’s pipeline has caught your eye, this could be a good moment to broaden your search and check out 39 healthcare AI stocks

With Vaxcyte still in the loss-making, pre-revenue stage yet trading at a multi billion US$ valuation, the question for you is simple: is this pipeline being undervalued, or is the market already pricing in years of future growth?

Most Popular Narrative: 56.6% Undervalued

Vaxcyte last closed at $47.36, while the most followed narrative anchors on a fair value of $109 based on long term vaccine opportunities and funding runway.

Expanded adult pneumococcal vaccination recommendations in the US and increasing adoption of adult PCV programs internationally are enlarging the addressable market for higher valency vaccines such as VAX-31. This directly relates to potential future revenue scale.

Want to understand why this narrative assigns such a high value to a company with no current revenue and ongoing losses? The core assumptions revolve around steep revenue ramp up, a sharp swing toward industry style margins, and a valuation multiple that leans heavily on those projected earnings. Curious how those ingredients combine to support a fair value more than double the last close?

Result: Fair Value of $109 (UNDERVALUED)

However, this depends on complex late stage trials and large scale manufacturing going to plan, and on future vaccine guidelines not favoring rival products instead.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment in this article leaning positive but still balanced, now is a good time to check the data yourself and decide where you stand, including weighing 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop with just one stock today, you might miss other opportunities that better fit your goals, risk comfort, and time horizon.

• Target value first and see which companies currently screen as 49 high quality undervalued stocks for potentially more compelling price tags.
• Prioritise resilience by reviewing 61 resilient stocks with low risk scores, so your watchlist is not built only on higher volatility stories.
• Get ahead of the crowd by scanning the screener containing 21 high quality undiscovered gems before they sit on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.